|
110 Companies |
|
139 Products |
|
139 Products |
|
95 Mechanisms of Action |
|
2 Trials |
|
919 News |
|
| «12345678910111213...1819» |
- triamcinolone acetonide / Generic mfg.
New P3 trial: Evaluation of Green Tea as Antioxidant Agent in Management of Oral Lichen Planus (clinicaltrials.gov) - Jan 2, 2015
P3, N=40, Completed, Sponsor: Cairo University
- | New P1/2 trial: Natural Gels for Treatment of Plaque Psoriasis (clinicaltrials.gov) - Jan 2, 2015
P1/2, N=52, Not yet recruiting, Sponsor: Secret of Youth
- Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
HEOR: Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation (clinicaltrials.gov) - Jan 2, 2015
P=N/A, N=40, Recruiting, Sponsor: University Hospital Case Medical Center
- || Cosentyx (secukinumab) / Novartis
Trial primary completion date: AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis (clinicaltrials.gov) - Dec 29, 2014
P2, N=276, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: May 2015 --> May 2017
- ||||||| Cosentyx (secukinumab) / Novartis
Trial completion: FUTURE 1: Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (clinicaltrials.gov) - Dec 29, 2014
P3, N=606, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: May 2015 --> May 2017 Active, not recruiting --> Completed
- Enbrel (etanercept) / Pfizer, Amgen
Clinical: DERM: An Observational Monocentric Study Investigating the Association Between Trough Serum Levels of Etanercept, Antibodies Towards Etanercept and Its Effectiveness in Psoriasis Patients (clinicaltrials.gov) - Dec 24, 2014
P=N/A, N=50, Not yet recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
- | WP1220 / WPD Pharma
Trial completion, Enrollment change: Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis (clinicaltrials.gov) - Dec 24, 2014
P2, N=21, Completed, Sponsor: Moleculin, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=30 --> 21
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate (clinicaltrials.gov) - Dec 24, 2014
P3, N=114, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed | N=30 --> 21 Active, not recruiting --> Completed
- | rose bengal disodium (PH-10) / Provectus
New P2 trial: A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10 (clinicaltrials.gov) - Dec 22, 2014
P2, N=30, Not yet recruiting, Sponsor: Provectus Pharmaceuticals
- Biomarker, Trial primary completion date: Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=200, Recruiting, Sponsor: George Washington University
Active, not recruiting --> Completed Trial primary completion date: Jul 2014 --> Jun 2015
- Trial primary completion date: A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=370, Recruiting, Sponsor: George Washington University
Trial primary completion date: Jul 2014 --> Jun 2015 Trial primary completion date: Jul 2014 --> Jul 2015
- | Enbrel (etanercept) / Pfizer, Amgen
Enrollment change: EVIP: Etanercept and Vascular Function in Psoriasis (clinicaltrials.gov) - Dec 19, 2014
P2, N=24, Completed, Sponsor: Emory University
Trial primary completion date: Jul 2014 --> Jul 2015 N=34 --> 24
- Enrollment change, Trial termination, Trial primary completion date: Determination of the Efficacy and Safety of Psoralait Versus Placebo in the Treatment of Psoriasis (clinicaltrials.gov) - Dec 19, 2014
P4, N=15, Terminated, Sponsor: Trima, Israel Pharmaceutical Products
N=34 --> 24 N=180 --> 15 | Recruiting --> Terminated | Trial primary completion date: Sep 2012 --> Mar 2013; Difficulties arouse in recruiting new patients
- |||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Trial completion, Trial primary completion date: Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - Dec 19, 2014
P2a, N=142, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
N=180 --> 15 | Recruiting --> Terminated | Trial primary completion date: Sep 2012 --> Mar 2013; Difficulties arouse in recruiting new patients Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Sep 2014
- |||| Cosentyx (secukinumab) / Novartis
Trial primary completion date: SIGNATURE: Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants. (clinicaltrials.gov) - Dec 19, 2014
P3, N=288, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Sep 2014 Trial primary completion date: Oct 2015 --> Jun 2016
- |||| Cibinqo (abrocitinib) / Pfizer
Enrollment open: Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis (clinicaltrials.gov) - Dec 19, 2014
P2, N=196, Recruiting, Sponsor: Pfizer
Trial primary completion date: Oct 2015 --> Jun 2016 Not yet recruiting --> Recruiting
- Xeljanz (tofacitinib) / Pfizer, PF-06263276 / Pfizer
Clinical: A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis (clinicaltrials.gov) - Dec 12, 2014
P1, N=20, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2014 --> Feb 2015
- ||||| Enbrel (etanercept) / Pfizer, Amgen, Yisaipu (etanercept biosimilar) / Cipla, 3SBio, Abbott
New P4 trial: Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate (clinicaltrials.gov) - Dec 10, 2014
P4, N=488, Recruiting, Sponsor: Zhejiang University
- |||||||||| Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
New P3 trial: Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet (clinicaltrials.gov) - Dec 8, 2014
P3, N=200, Not yet recruiting, Sponsor: LEO Pharma
- ||| brepocitinib (PF-06700841) / Pfizer
PK/PD data: A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation (clinicaltrials.gov) - Dec 8, 2014
P1, N=104, Recruiting, Sponsor: Pfizer
- |||| Xeljanz (tofacitinib) / Pfizer
Clinical: Tofacitinib Ointment For Chronic Plaque Psoriasis (clinicaltrials.gov) - Dec 7, 2014
P2, N=476, Completed, Sponsor: Pfizer
Trial primary completion date: Oct 2014 --> Feb 2015 Active, not recruiting --> Completed
- ||| Clinical: Cytokines and Vascular Inflammation in Psoriasis (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=96, Completed, Sponsor: Innovaderm Research Inc.
- | Phase classification: A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector (clinicaltrials.gov) - Dec 6, 2014
P0, N=68, Completed, Sponsor: Centocor, Inc.
Active, not recruiting --> Completed Phase classification: P=N/A --> P0
- | Enbrel (etanercept) / Pfizer, Amgen
Phase classification: Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis (clinicaltrials.gov) - Dec 5, 2014
P4, N=128, Recruiting, Sponsor: Pfizer
Phase classification: P=N/A --> P0 Phase classification: P=N/A --> P4
- nystatin oral / Generic mfg.
Enrollment closed, Trial primary completion date: The Use of Probiotics in Patients With Symptomatic Oral Lichen Planus (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=120, Active, not recruiting, Sponsor: University of Copenhagen
Phase classification: P=N/A --> P4 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Nov 2015
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Trial completion, Trial primary completion date, IO biomarker: Regulatory T-cells in Psoriasis Patients as Targets for Therapy (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=38, Completed, Sponsor: University of Aberdeen
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Nov 2015 Recruiting --> Completed | Trial primary completion date: Aug 2011 --> Sep 2013
- ||| seletalisib (UCB5857) / UCB
New P1 trial: Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject (clinicaltrials.gov) - Dec 1, 2014
P1, N=57, Completed, Sponsor: UCB Pharma
- cyclosporine / Generic mfg.
Enrollment change, Trial withdrawal: The Effectiveness of Lower Cyclosporine Doses for Psoriasis (clinicaltrials.gov) - Nov 24, 2014
P2, N=0, Withdrawn, Sponsor: University of Rochester
Recruiting --> Completed | Trial primary completion date: Aug 2011 --> Sep 2013 N=17 --> 0 | Terminated --> Withdrawn
- ||||| toreforant (JNJ-38518168) / J&J
New P2 trial: A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) - Nov 20, 2014
P2, N=66, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | Tremfya (guselkumab) / J&J
Trial completion: A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis (clinicaltrials.gov) - Nov 19, 2014
P2, N=49, Completed, Sponsor: Janssen Pharmaceutical K.K.
N=17 --> 0 | Terminated --> Withdrawn Active, not recruiting --> Completed
- Enrollment change, Trial withdrawal: Efficacy of Aerosal® in the Treatment of Inverse Psoriasis and Sebopsoriasis (clinicaltrials.gov) - Nov 18, 2014
P2, N=0, Withdrawn, Sponsor: Tecno Sun SRL
Active, not recruiting --> Completed N=64 --> 0 | Recruiting --> Withdrawn
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE) (clinicaltrials.gov) - Nov 18, 2014
P=N/A, N=548, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=64 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed
- |||| Xeljanz (tofacitinib) / Pfizer
Clinical: OPAL BEYOND: Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors (clinicaltrials.gov) - Nov 18, 2014
P3, N=390, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Trial primary completion date: Apr 2015 --> Jan 2016
- ||| Enrollment closed: EPIDEPSO: Clinical Assessment and Psychosocial Impact of Psoriasis (clinicaltrials.gov) - Nov 13, 2014
P4, N=800, Active, not recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
Trial primary completion date: Apr 2015 --> Jan 2016 Recruiting --> Active, not recruiting
- erlotinib / Generic mfg.
Enrollment change: Erlotinib for Treatment of Psoriasis (clinicaltrials.gov) - Nov 10, 2014
P2, N=0, Withdrawn, Sponsor: Northwestern University
Recruiting --> Active, not recruiting N=45 --> 0
- Trial primary completion date, Patient reported outcomes: Post Marketing Observational Study on Venezuelan Patients With Psoriasis (clinicaltrials.gov) - Nov 6, 2014
P=N/A, N=100, Suspended, Sponsor: AbbVie (prior sponsor, Abbott)
N=45 --> 0 Trial primary completion date: Sep 2014 --> Nov 2015
- ||||| pefcalcitol (M 518101) / Maruho
Enrollment closed: Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis (clinicaltrials.gov) - Nov 5, 2014
P3, N=360, Active, not recruiting, Sponsor: Maruho North America Inc.
Trial primary completion date: Sep 2014 --> Nov 2015 Recruiting --> Active, not recruiting
- ||| Trial completion, Enrollment change: An Exploratory Genetic Study in Participants With Psoriasis (clinicaltrials.gov) - Nov 3, 2014
P0, N=712, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed | N=250 --> 712
- |||| Xeljanz (tofacitinib) / Pfizer
Clinical: A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis (clinicaltrials.gov) - Oct 30, 2014
P3, N=264, Recruiting, Sponsor: Pfizer
Enrolling by invitation --> Completed | N=250 --> 712 Trial primary completion date: Aug 2015 --> Nov 2014
- ||| calcipotriol/betamethasone dipropionate / Generic mfg.
Trial completion, Enrollment change: Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation (clinicaltrials.gov) - Oct 30, 2014
P=N/A, N=561, Completed, Sponsor: LEO Pharma
Trial primary completion date: Aug 2015 --> Nov 2014 Active, not recruiting --> Completed | N=1000 --> 561
- Enrollment open: Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Psoriasis (clinicaltrials.gov) - Oct 27, 2014
P=N/A, N=60, Recruiting, Sponsor: Pontificia Universidad Catolica de Chile
Active, not recruiting --> Completed | N=1000 --> 561 Not yet recruiting --> Recruiting
- ||| Clinical: A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis (clinicaltrials.gov) - Oct 24, 2014
P0, N=1131, Completed, Sponsor: Janssen Pharmaceutica
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: Study to Assess the Immunogenicity and Safety of Etanercept Produced in Plaque Psoriasis (clinicaltrials.gov) - Oct 24, 2014
P4, N=118, Not yet recruiting, Sponsor: Amgen
- | Xeljanz (tofacitinib) / Pfizer
Clinical: Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - Oct 24, 2014
P2, N=12, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Phase classification: P2a --> P2 | N=42 --> 12 | Trial primary completion date: Feb 2015 --> Nov 2013
- |||| Xeljanz (tofacitinib) / Pfizer
Clinical: A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - Oct 23, 2014
P3, N=3200, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed | Phase classification: P2a --> P2 | N=42 --> 12 | Trial primary completion date: Feb 2015 --> Nov 2013 Trial primary completion date: Apr 2017 --> Feb 2018
- Clinical: Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Psoriasis (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=60, Not yet recruiting, Sponsor: Pontificia Universidad Catolica de Chile
- Trial primary completion date: IL-17 Role in Variants of Psoriasis (clinicaltrials.gov) - Oct 20, 2014
P=N/A, N=90, Active, not recruiting, Sponsor: Innovaderm Research Inc.
Trial primary completion date: Apr 2017 --> Feb 2018 Trial primary completion date: Aug 2014 --> Nov 2014
- | neihulizumab (ALTB-168) / AltruBio
New P2 trial: A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis (clinicaltrials.gov) - Oct 17, 2014
P2, N=15, Not yet recruiting, Sponsor: AbGenomics B.V Taiwan Branch
- |||| Cosentyx (secukinumab) / Novartis
P3 data, Trial primary completion date: 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis (clinicaltrials.gov) - Oct 15, 2014
P3, N=675, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2014 --> Nov 2014 Trial primary completion date: May 2015 --> Apr 2017
- Enbrel (etanercept) / Pfizer, Amgen
Clinical: Safety and Efficacy of Etanercept in Patients With Psoriasis (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=80, Recruiting, Sponsor: Chengdu PLA General Hospital